Neukio Biotherapeutics (Xingyon Biotechnology) Overview
Executive Summary
Neukio Biotherapeutics, legally operating as Neukio (Shanghai) Biotherapeutics Co., Ltd. / Xingyon (Shanghai) Biotechnology Co., Ltd., is a clinical-stage biotechnology company focused on the development of induced pluripotent stem cell (iPSC)-derived immune cell therapies. Established in June 2021 and headquartered in the Shanghai Waigaoqiao Free Trade Zone, China, Neukio specializes in designing and manufacturing off-the-shelf, allogeneic cell products. The company primarily targets refractory solid tumors and autoimmune diseases, seeking to overcome the high manufacturing costs, batch-to-batch variability, and supply chain constraints associated with autologous CAR-T therapies.
Neukio operates an integrated research, development, and industrial manufacturing infrastructure covering approximately 6,000 square meters. Through its proprietary platforms, the company optimizes gene editing, 3D bioreactor suspension expansion, and cell banking to deliver scalable immune cell medicines.
Continue…
Core Technologies and R&D Platforms
Neukio's core operational capabilities revolve around three primary technical pillars:
1. Precision Gene Editing and iPSC Platform
Neukio utilizes iPSCs as a single, expandable seed source for cellular therapy. By capitalizing on the single-cell clonality of iPSCs, Neukio introduces precise genetic modifications before cell differentiation. This includes:
* Insertion of Chimeric Antigen Receptors (CAR) targeting specific tumor-associated antigens.
* Knockouts of immune checkpoint pathways or genes responsible for immune suppression.
* Insertion of functional transgenes designed to enhance immune cell infiltration, survival, and persistence within the tumor microenvironment (TME).
Unlike primary adult cell editing, the iPSC platform allows iterative genomic editing, single-clone isolation, and rigorous sequence verification prior to master cell banking.
2. Bioprocess Development and Scalable Manufacturing
Neukio has developed a standardized, continuous process development platform for cell conversion:
* Three-Tiered Cell Banking: Establishes Master Cell Banks (MCB) and Working Cell Banks (WCB) from fully validated, gene-edited iPSC clones.
* Serum-Free & Feeder-Free Culture Systems: Eliminates reliance on animal-derived components and feeder cell co-cultures, reducing potential contamination, immunogenicity, and regulatory hurdles.
* 3D Bioreactor Suspension Process: Operates scalable, automated 3D bioreactors equipped with continuous perfusion systems to differentiate iPSCs into mature, functional iNK or iT cells at industrial scale.
* Safety and Purity Controls: Removes residual undifferentiated iPSCs to eliminate tumorigenic risks, delivering consistent final dosages.
3. Dual CAR-iNK and CAR-iT Platforms + In Vivo CAR Technology
Neukio advances two complementary cell platforms simultaneously:
* CAR-iNK (iPSC-derived Natural Killer Cells): Utilizes antigen-independent innate immunity mechanism (e.g., ADCC via CD16 and direct cytotoxicity) alongside engineered CAR targeting to kill heterogeneous tumor populations without causing Graft-versus-Host Disease (GvHD), cytokine release syndrome (CRS), or neurotoxicity.
* CAR-iT (iPSC-derived T Cells): Engineered to maintain enhanced in vivo activation, proliferation, and long-term memory persistence.
* In Vivo CAR Technology: Preclinical R&D exploring viral and non-viral delivery modalities to directly program immune cells in vivo.
Pipeline, Products, and Offerings
Neukio is an innovative drug developer rather than a traditional contract services provider. Its pipeline features multiple proprietary cell therapy candidates targeting solid tumors and severe autoimmune conditions.
Therapeutic Pipeline Overview
- CAR-iNK Candidates: Neukio maintains a multi-target, multi-mechanism iNK candidate pipeline. Three lead candidates have advanced into early-stage clinical validation / investigator-initiated trials (IIT) targeting high-incidence solid tumors (including gastrointestinal cancers and non-small cell lung cancer).
- CAR-iT Candidates: Preclinical iT candidates focused on solid tumor penetration and resistance to immunosuppressive factors, nearing investigational new drug (IND) enablement.
- Autoimmune Indications: Applications of off-the-shelf CAR-iNK and CAR-iT cells for targeted depletion of pathogenic autoreactive B cells and plasma cells in severe autoimmune disorders.
Strategic Partnerships and Licensing Services
Neukio leverages its process development and manufacturing assets to form strategic business development (BD) partnerships:
* Out-Licensing & In-Licensing: Co-development and commercial rights licensing for proprietary CAR constructs, specific engineered iPSC lines, or target-specific iNK/iT candidates.
* Industrialization & CMC Collaboration: Joint process development and biomanufacturing tech transfers with biopharmaceutical firms, equipment vendors, and research institutions (e.g., specialized bioreactor scale-up and automated cell culture workflows).
Corporate History and Key Milestones
- June 2021: Founded in the Shanghai Waigaoqiao Free Trade Zone, China.
- July 2021: Closed a $40 million Angel Financing round led by Lilly Asia Ventures, alongside Sherpa Healthcare Partners and IDG Capital.
- December 2021: Fully completed construction and validation of a 6,000 m² R&D and cGMP biomanufacturing facility in Shanghai.
- September 2022: Closed a $58 million Series A Financing round led by CD Capital, with participation from Yahui Investment, Kuan Capital, Alibaba Health, and Panlin Capital.
- 2023–2024: Advanced multiple iNK programs into clinical validation, expanded automated 3D bioreactor capabilities, and established strategic manufacturing collaborations.
